Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature

CONCLUSIONS AND IMPORTANCE: ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.PMID:37644808 | DOI:10.1177/11206721231199120
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Source Type: research